Effect of Tivorel on the level of matrix metalloproteinases-2 and 9, galectin-3, final glycation products and functional state of the endothelium in patients with postinfarction chronic heart failure with preserved ejection fraction

О. В. Курята, А. Забіда, О. Ю. Сіренко


The objective: to evaluate the effect of Tivor-L (20 mg levocarnitine + 42 mg arginine hydrochloride, Yuriya-Pharm) on AGEs, galectin-3, MMP-2,9 serum level, cardiac haemodynamics and endothelial function in patients with post infarction HFpEF.

Materials and methods. All individuals (35) included aged 40 to 80 years, 23 (66%) males and 12 (34%) females were diagnosed with (HFpEF) according to ESC guidelines (2016). First (1-st ) group (n=15) pts with postinfarction HFpEF treated with Tivor-L in addition to standard treatment for Chronic heart failure (CHF). Second (2nd) group (n=20) – pts with postinfarction HFpEF with standard treatment for CHF without Tivor-L. All the patients included in 1st group got Tivor-L intravenously daily for 10 days in addition to the conventional therapy. General biochemical blood analysis, complete blood count and glomerular filtration rate, MMP-2, MMP-9, galectin-3 and AGEs serum levels were determined before and after treatment.

Results. Mean galectin-3 level in 1st was decreased by 16.4 % on the whole (p<0,05), in compare with standard therapy – no significant changes (p>0,05). significant decreasing of MMP-2, MMP-9 levels on 41% and 78,5% in 1st group (p<0,05). The FMD level was significantly higher in 1st group than in standard therapy group (p<0,05). Endothelial function normalizing was achieved in 10 (66%) of 1st group patients.

Conclusion. Most of the pts with postinfarction HFpEF have increased AGEs serum level, and endothelial dysfunction. There were a significant decrease in galectin-3 and MMP-2, MMP-9 serum levels after adding of Tivor-L to the conventional treatment for chronic heart failure.


postinfarction heart failure; matrix metalloproteinase; galectin-3


Kostis WJ, Deng Y, Moreyra AE, Pantazopoulos JS, Kostis JB. No decrease in the incidence of heart failure following acute myocardial infarction in the years 1994–2006. Circulation. 2011;124:A17546.

Ezekowitz JA, Kaul P, Bakal JA, Armstrong PW, Welsh RC, McAlister FA. Declining in-hospital mortality and increasing heart failure incidence in elderly patients with first myocardial infarction. J Am Coll Cardiol. 2009;53:13–20.

Gheorghiade M, Bonow RO. Chronic heart failure in the United States: a manifestation of coronary artery disease. Circulation. 1998;97:282–289.

Kostis WJ, Deng Y, Pantazopoulos JS, Moreyra AE, Kostis JB; Myocardial Infarction Data Acquisition System (MIDAS14) Study Group. Trends in mortality of acute myocardial infarction after discharge from the hospital. Circ Cardiovasc Qual Outcomes. 2010;3:581–589.

Gerber Y, Weston SA, Berardi C, McNallan SM, Jiang R, Redfield MM, Roger VL. Contemporary trends in heart failure with reduced and preserved ejection fraction after myocardial infarction: a community study. Am J Epidemiol. 2013;178:1272–1280.

Chen J, Hsieh AF, Dharmarajan K, Masoudi FA, Krumholz HM. National trends in heart failure hospitalization after acute myocardial infarction for Medicare beneficiaries: 1998-2010. Circulation. 2013;128:2577–2584.

Borlaug BA, Paulus WJ. Heart failure with preserved ejection fraction: pathophysiology, diagnosis, and treatment. Eur Heart J. 2011;32:670– 679.

Jhund PS, McMurray JJ. Heart failure after acute myocardial infarction: a lost battle in the war on heart failure? Circulation. 2008;118:2019– 2021.

Wilson EM. Region– and type-specific induction of matrix metalloproteinases in post-myocardial infarction remodelling / Wilson EM, Moainie SL, Baskin JM et al. // Circulation. – 2003. – Vol. 107 (22). – P. 2857–63.

Mukherjee R. Myocardial infarct expansion and matrix metalloproteinase inhibition / Mukherjee R, Brinsa TA, Dowdy KB. et al. // Circulation. – 2003. – Vol. 107 (4). – P. 618–25.

Tsai TH. Value and level of galectin-3 in acute myocardial infarction patients undergoing primary percutaneous coronary intervention / Tsai TH, Sung PH, Chang LT et al. // J. Atheroscler. Thromb. – 2012. – Vol. 19. – P. 1073–1082.

Sundararaj KP. Interleukin-6 released from fibroblasts is essential for upregulation of matrix metalloproteinase-1 expression by u937 macrophages in coculture-crosstalking between fibroblasts and u937 macrophages exposed to high glucose / Sundararaj KP, Samuvel DJ, Sanders JJ, et al. // J. Biol. Chem. – 2009. – Vol. 284. – P. 13714–13724.

Saksida T. Galectin-3 deficiency protects pancreatic islet cells from cytokine-triggered apoptosis in vitro / Saksida T, Nikolic I, Vujicic M, et al. // J Cell Physiol. – 2013. – Vol. 228. – P. 1568–76.

R. A. de Boer. Galectin-3: a novel mediator of heart failure development and progression / R. A. de Boer, A. A. Voors, P. Muntendam, et al. // European Journal of Heart Failure. – 2009. – Vol. 11. – N. 9. – P. 811–817.

Hartog JW, Voors AA, Bakker SJ, et al. Advanced glycation endproducts (AGEs) and heart failure: pathophysiology and clinical implications. Eur J Heart Fail. 2007;9:1146-55.

Kuryata O. V., Abdunaser A. Zabida. Effect of L-Arginine on the Serum Level of Advanced Glycation End Products in Patients with Post Infarction Chronic Heart Failure. Journal of Nutritional Therapeutics. 2017; 6(2):43–50.

Kuryata O, Sirenko O (2017) Endothelial Function, Insulin Resistance, Serum Adiponectin Level in Rheumatoid Arthritis Females with Renal Dysfunction and Its Dynamics with L-Arginine Aspartate Supplementation . Prensa Med Argent 103:6.

Koifman B, Wollam Y, Bogomolny N et al. Improvement of cardiac performance by intravenous infusion of L-arginine in patients with moderate congestive cardiac failure. J Am Coll Cardiol 1995;26:1251–1256.

W.Doehner,M. Frenneaux, and S.D. Anker, Metabolic impairment in heart failure: the myocardial and systemic perspective, Journal of the American College of Cardiology, vol. 64, no. 13, pp. 1388–1400, 2014.

R. Ferrari, E. Merli, G. Cicchitelli, D. Mele, A. Fucili, and C. Ceconi, Therapeutic effects of L-carnitine and propionyl-Lcarnitine on cardiovascular diseases: a review, Annals of the New York Academy of Sciences, vol. 1033, pp. 79–91, 2004.

L. H. Opie, Proof that glucose-insulin-potassium provides metabolic protection of ischaemic myocardium? Lancet, vol. 353, no. 9155, pp. 768–769, 1999.

Graham HK, Horn M, Trafford AW. Extracellular matrix profiles in the progression to heart failure. European Young Physiologists Symposium Keynote Lecture-Bratislava 2007. Acta Physiol (Oxf). 2008; 194(1):3–21.

Hung CS, Chou CH, Wu XM, Chang YY, Wu VC, Chen YH, Chang YS, Tsai YC, Su MJ, Ho YL, Chen MF, Wu KD, Lin YH. Circulating tissue inhibitor of matrix metalloproteinase-1 is associated with aldosterone-induced diastolic dysfunction. J Hypertens. 2015; 33(9):1922–1930; discussion 1930.

Chang YY, Chen A, Wu XM, Hsu TP, Liu LY, Chen YH, Wu YW, Hsu RB, Lee CM, Wang SS, Lo MT, Chen MF, Lin YH. Comparison the Prognostic Value of Galectin-3 and Serum Markers of Cardiac Extracellular Matrix Turnover in Patients with Chronic Systolic Heart Failure. Int J Med Sci. 2014; 11(11): 1098–1106.

Kloner RA, Ellis SG, Lange R, Braunwald E. Studies of experimental coronary artery reperfusion. Effects on infarct size, myocardial function, biochemistry, ultrastructure and microvascular damage. Circulation 1983;68:I8–15.

Chen J, Tung CH, Allport JR, Chen S, Weissleder R, Huang PL. Near-infrared fluorescent imaging of matrix metalloproteinase activity after myocardial infarction. Circulation 2005;111:1800–5.

Wagner DR, Delagardelle C, Ernens I, Rouy D, Vaillant M, Beissel J. Matrix metalloproteinase-9 is a marker of heart failure after acute myocardial infarction. J Card Fail 2006;12:66–72.

A. P. Wong, A. Niedzwiecki, and M. Rath, «Myocardial energetics and the role of micronutrients in heart failure: a critical review», American Journal of Cardiovascular Disease, vol. 6, no. 3, pp. 81–92, 2016.

Wu G, Meininger CJ. Arginine nutrition and cardiovascular function. J Nutr 2000;130:2626–2629.

Wink DA, Hanbauer I, Grisham MB, et al. Chemical biology of nitric oxide: regulation and protective and toxic mechanisms. Curr Top Cell Regul 1996;34:159–187.

Copyright (c) 2020 О. В. Курята, А. Забіда, О. Ю. Сіренко

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

ISSN 2412-8708 (Online), ISSN 2307-5112 (Print)

Flag Counter

ISSN (print): 2307-5112.